These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 15751068)

  • 41. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
    Schvarcz R; Ando Y; Sönnerborg A; Weiland O
    J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S; Rogge J; Weaver L; Schafer DF
    Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
    Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
    Bagheri H; Fouladi A; Barange K; Lapeyre-Mestre M; Payen JL; Montastruc JL; Vinel JP
    Pharmacotherapy; 2004 Nov; 24(11):1546-53. PubMed ID: 15537560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
    Saadoun D; Thibault V; Si Ahmed SN; Alric L; Mallet M; Guillaud C; Izzedine H; Plaisier A; Fontaine H; Costopoulos M; Le Garff-Tavernier M; Hezode C; Pol S; Musset L; Poynard T; Cacoub P
    Ann Rheum Dis; 2016 Oct; 75(10):1777-82. PubMed ID: 26567178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
    Babatin M; Schindel L; Burak KW
    Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
    Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
    Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.
    Esmat G; El Kassas M; Hassany M; Gamil M; El Raziky M
    Liver Int; 2014 Feb; 34 Suppl 1():24-8. PubMed ID: 24373075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.
    Hamidah A; Thambidorai CR; Jamal R
    Med J Malaysia; 2005 Oct; 60(4):517-9. PubMed ID: 16570722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.
    Alric L; Plaisier E; Thébault S; Péron JM; Rostaing L; Pourrat J; Ronco P; Piette JC; Cacoub P
    Am J Kidney Dis; 2004 Apr; 43(4):617-23. PubMed ID: 15042538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C virus-related cryoglobulinemic vasculitis.
    Mazzaro C; Mauro E; Ermacora A; Doretto P; Fumagalli S; Tonizzo M; Toffolutti F; Gattei V
    Minerva Med; 2021 Apr; 112(2):175-187. PubMed ID: 33198444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
    Chowdhury R; Tsen A
    Am J Kidney Dis; 2017 Aug; 70(2):301-304. PubMed ID: 28343737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.